Announcement • Jun 09
M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026 M3, Inc. announced that they will report Q1, 2027 results on Aug 06, 2026 Announcement • Jun 05
M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK. M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK on June 5, 2026.
For the period ending June 30, 2025, Wiseman Co. Ltd reported total revenue of ¥12.38 billion, operating loss of ¥222 million and net loss of ¥170 million. As of June 30, 2025, Wiseman Co. Ltd reported total assets of ¥20.03 billion and total common equity of ¥2.74 billion.
The expected completion of the transaction is July 1, 2026. Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 02
M3, Inc., Annual General Meeting, Jun 26, 2026 M3, Inc., Annual General Meeting, Jun 26, 2026. Announcement • Apr 22
M3, Inc. to Report Fiscal Year 2026 Results on May 01, 2026 M3, Inc. announced that they will report fiscal year 2026 results on May 01, 2026 Announcement • Nov 29
M3, Inc. to Report Q3, 2026 Results on Feb 04, 2026 M3, Inc. announced that they will report Q3, 2026 results on Feb 04, 2026 Announcement • Sep 04
Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion. Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion on September 2, 2025. A cash consideration of ¥19.08 billion will be paid by Intermestic Inc. As part of consideration, ¥19.08 billion is paid towards common equity of Horus Co., Ltd. The transaction will be financed through senior debt of ¥18 billion.
For the period ending April 30, 2025, Horus Co., Ltd. reported total revenue of ¥28.19 billion and EBIT of ¥1.84 billion. As of April 30, 2025, Horus Co., Ltd. reported total assets of ¥19.95 billion and total common equity of ¥4.42 billion.
The expected completion of the transaction is October 1, 2025. Announcement • Sep 01
M3, Inc. to Report Q2, 2026 Results on Nov 12, 2025 M3, Inc. announced that they will report Q2, 2026 results on Nov 12, 2025 Announcement • Jun 05
EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders. EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders on June 5, 2025. EUCALIA Inc acquired 0.053 shares in Epigno Inc. The sellers were 19.9% stake from M3, Inc., 9.4% stake from M3 Career, Inc., 11.7% stake from THVP-No. 1 Limited Partnership, a fund managed by Tohoku University Venture Partners Co.,Ltd., 22.5% stake from Fumiyoshi Inui,12.1% stake from Takuya Shiga. The other sellers were Lifetime Ventures Investment LP, Kanshin Mirai No.2 Investment LP, Healthcare New Frontier Investment LP, and Colopl Next No.7 Fund Investment LP.
For the period ending August 31, 2024, Epigno Inc. reported total revenue of approximately ¥110 million, operating loss of ¥83.7 million, net loss of ¥81.19 million, total assets of approximately ¥190 million and net assets of ¥23.3 million. The transaction is expected to close on July 1, 2025. Announcement • May 31
M3, Inc. to Report Q1, 2026 Results on Aug 06, 2025 M3, Inc. announced that they will report Q1, 2026 results on Aug 06, 2025 Announcement • May 03
M3, Inc. (TSE:2413) announces an Equity Buyback for 20,000,000 shares, representing 2.95% for ¥20,000 million. M3, Inc. (TSE:2413) announces a share repurchase program. Under the program, the company will repurchase up to 20,000,000 shares, representing 2.95% of its total shares outstanding (excluding treasury shares), for a total of ¥20,000 million. The purpose of repurchase program is to provide returns to shareholders. The repurchase program is valid till April 30, 2026. As of March 31, 2025, the company had 679,032,629 shares issued (excluding treasury shares) and 45,271 treasury shares Announcement • Mar 07
M3, Inc. (TSE:2413) entered into Share transfer agreement to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion. M3, Inc. (TSE:2413) agreed to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion on March 5, 2025. A cash consideration of ¥10.2 billion will be paid by M3, Inc. As part of consideration, ¥10.2 billion is paid towards common equity of Ewel Inc. The transaction will be financed through Cash on Hand of ¥10.2 billion.
For the period ending March 31, 2024, Ewel Inc. reported total revenue of ¥11.67 billion, EBIT of ¥887 million and net income of ¥566 million. As of March 31, 2024, Ewel Inc. reported total assets of ¥13.65 billion and total common equity of ¥5.88 billion.
The expected completion of the transaction is April 1, 2025. Announcement • Mar 01
M3, Inc. to Report Fiscal Year 2025 Results on May 02, 2025 M3, Inc. announced that they will report fiscal year 2025 results on May 02, 2025 Announcement • Feb 10
M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025 M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75. Announcement • Nov 30
M3, Inc. to Report Q3, 2025 Results on Feb 10, 2025 M3, Inc. announced that they will report Q3, 2025 results on Feb 10, 2025 Reported Earnings • Nov 01
Second quarter 2025 earnings released: EPS: JP¥8.90 (vs JP¥16.19 in 2Q 2024) Second quarter 2025 results: EPS: JP¥8.90 (down from JP¥16.19 in 2Q 2024). Revenue: JP¥60.6b (up 3.8% from 2Q 2024). Net income: JP¥6.05b (down 45% from 2Q 2024). Profit margin: 10.0% (down from 19% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Healthcare Services industry in Europe. Valuation Update With 7 Day Price Move • Oct 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €10.30, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €13.60 per share. Announcement • Aug 27
M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024 M3, Inc. announced that they will report Q2, 2025 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €8.75, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €14.82 per share. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €7.45, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Healthcare Services industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €14.26 per share. Reported Earnings • Jul 29
First quarter 2025 earnings released: EPS: JP¥16.57 (vs JP¥18.29 in 1Q 2024) First quarter 2025 results: EPS: JP¥16.57 (down from JP¥18.29 in 1Q 2024). Revenue: JP¥64.2b (up 12% from 1Q 2024). Net income: JP¥11.2b (down 9.4% from 1Q 2024). Profit margin: 18% (down from 22% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Announcement • Jun 03
M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024 M3, Inc. announced that they will report Q1, 2025 results on Jul 26, 2024 Reported Earnings • May 01
Full year 2024 earnings released: EPS: JP¥66.68 (vs JP¥72.22 in FY 2023) Full year 2024 results: EPS: JP¥66.68 (down from JP¥72.22 in FY 2023). Revenue: JP¥238.9b (up 3.5% from FY 2023). Net income: JP¥45.3b (down 7.7% from FY 2023). Profit margin: 19% (down from 21% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Buy Or Sell Opportunity • Apr 25
Now 20% overvalued Over the last 90 days, the stock has fallen 25% to €11.20. The fair value is estimated to be €9.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 10.0% per annum. Earnings are also forecast to grow by 12% per annum over the same time period. Board Change • Mar 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. 
